Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382650 · ClinicalTrials.gov registry record
Survey of Human Rabies Immune Globulin Safety in Children
A clinical trial, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- 35
- Enrollment target
NCT05382650: Clinical Trial study, sponsored by The Methodist Hospital Research Institute.
NCT05382650 is a clinical trial that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382650 was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- 35 participants
- Enrollment target
Study Summary
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.
Primary Outcome
Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration
Interventions
- BIOLOGICAL Human rabies immune globulin 300 IU/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2025-10-15 |
Why NCT05382650 stopped before completion
NCT05382650 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Human rabies immune globulin 300 IU/mL is the first listed.
NCT05382650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05382650 about?
NCT05382650 is a clinical study titled "Survey of Human Rabies Immune Globulin Safety in Children". This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric pa...
What is the current status of trial NCT05382650?
This trial is currently terminated. The enrollment target is 35 participants. The study started on 2023-02-22. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT05382650?
The interventions under investigation include: Human rabies immune globulin 300 IU/mL (BIOLOGICAL).
Who is sponsoring clinical trial NCT05382650?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI